Steady-state plasma concentrations of midazolam in critically ill infants and children

Annals of Pharmacotherapy

Volumn 30, Issue 1, 1996, Pages 27-30

  Hughes, Julie ^a   Gill, Andrea M ^a   Mulhearn, Helen ^b   Powell, Edward ^b   Choonara, Imti ^a  

^a ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^b Sefton General Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MIDAZOLAM;

ADOLESCENT; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG INFUSION; HUMAN; INFANT; PLASMA CLEARANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEDATION; STEADY STATE;

EID: 0030025176     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000104     Document Type: Article

References (29)

1. Booker PD, Beechey A, Lloyd-Thomas AR. Sedation of children requiring artificial ventilation using an infusion of midazolam. Br J Anaesth 1986;58-1104-8.
2. Matthews AJ. An audit of sedation, analgesia and muscle relaxation in paediatric intensive care in the United Kingdom. Paediatr Anaesth 1993;3:107-15.
3. Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses Anesthesiology 1985;62:310-24.
4. Twersky RS, Hartung J, Berger BJ, McClam J, Beaton C. Midazolam enhances anterograde but not retrograde amnesia in pediatric patients. Anesthesiology 1993;78:51-5.
5. Mathews HML, Carson IW, Lyons SM, Orr IA, Collier PS, Howard PJ, et al A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. Br J Anaesth 1988;61:302-7.
6. Jacqz-Aigrain E, Wood C, Robieux I. Pharmacokinetics of midazolam in critically ill neonates. Eur J Clin Pharmacol 1990,39:191-2.
7. Jacqz-Aigrain E, Daoud P, Burtin P, Maherzi S, Beaufils F. Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. Eur J Clin Pharmacol 1992;42:329-32.
8. Pons G, Carrier O, Richard MO, Rey E, d'Athis P, Moran C, et al. Developmental changes of caffeine elimination in infancy. Dev Pharmacol Ther 1988;11:258-64.
9. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, et al A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993.53:298-305.
10. Blackett A, Dhillon S, Cromarty JA. Rapid and sensitive high-performance liquid Chromatographic assay for midazolam and 1-hydroxymidazolam. the major metabolite, in human serum J Chromatogr 1988;433:326-30.
11. Choonara IA, McKay P, Ham R, Rane A. Morphine metabolism in children. Br J Clin Pharmacol 1989.28:599-604.
12. Choonara I, Lawrence A, Michalkiewicz A, Bowhay A, Ratcliffe J. Morphine metabolism in neonates and infants. Br J Clin Pharmacol 1992;34:434-7.
13. McRorie TI, Lynn AM, Nespeca MK, Opheim KE, Slattery, JT. The maturation of morphine clearance and metabolism. Am J Disord Child 1992;146:972-6.
14. Payne K, Mattheyse, FJ, Liebenberg D, Dawes T. The pharmacokinetics of midazolam in paediatric patients. Eur J Clin Pharmacol 1989;37:267-72.
15. Jones RDM, Chan K, Roulson CJ, Brown AG, Smith ID, Mya GH. Pharmacokinetics of flumazenil and midazolam. Br J Anaesth 1993;70:286-92
16. Hughes J, Gill A, Leach ID, Nunn AJ, Billingham I, Ratcliffe J, et al. A prospective study of the adverse effects of midazolam on withdrawal in critically ill children. Acta Paediatr 1994;83:1194-9.
17. Dirksen MSC, Vree TB, Driessen J.I. Clinical pharmacokinetics of long-term infusion of midazolam in critically ill patients - preliminary results Anaesth Intensive Care 1987;15:440-4.
18. Shafer A, Doze VA, White PF. Pharmacokinetic variability of midazolam infusions in critically ill patients. Crit Care Med 1990;18:1039-41.
19. Oldenhof H, de Jong M, Steenhoek A, Janknegt R. Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? Clin Pharmacol Ther 1988;43:263-9
20. Lloyd-Thomas AR, Booker PD. Infusion of midazolam in paediatric patients after cardiac surgery. Br J Anaesth 1986;58:1109-15.
21. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;47:1643-53.
22. Macnab MSP, Macrae DJ, Guy E, Grant IS, Feely J. Profound reduction in morphine clearance and liver blood flow in shock Intensive Care Med 1986,12:366-9.
23. Leppik IE, Fisher J, Kriel R, Sawchuk RJ. Altered phenytoin clearance with febrile illness Neurology 1986;36:1367-70.
24. Gal P, Boer HR, Toback J, Wells TJ, Erkan NV. Effect of asphyxia on theophylline clearance in newborns. South Med J 1982;75:836-8.
25. Hartwig S, Roth B, Theisohn M. Clinical experience with continuous intravenous sedation using midazolam and fentanyl in the paediatric intensive care unit. Eur J Pediatr 1991;150:784-8.
26. Rey E, Delaunay L, Pons G, Murat I, Richard MO, Saint-Maurice C, et al. Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. Eur J Clin Pharmacol 1991;41:355-7.
27. Tolia V, Brennan S, Aravind MK, Kauffman RE. Pharmacokinetic and pharmacodynamic study of midazolam in children during esophagogastroduodenoscopy. J Pediatr 1991;119:467-71
28. Wells TG, Ellis EN, Casteel HB, Hendry IR, Kearns GL. Pharmacokinetics of single dose midazolam in children (abstract). Clin Pharmacol Ther 1991;49:160.
29. Marx CM, Smith PG, Lowrie LH, Hamlett KW, Ambuel B, Yamashita TS, et al. Optimal sedation of mechanically ventilated pediatric critical patients. Crit Care Med 1994;22:163-70.